 |
|
CLINICIAN’S CORNER
Medical Treatment of Peripheral Arterial Disease
Graeme J. Hankey, MD;
Paul E. Norman, DS;
John W. Eikelboom, MBBS, MSc
JAMA. 2006;295:547-553.
Context Peripheral arterial disease (PAD) affects approximately 20% of adults older than 55 years and is a powerful predictor of myocardial infarction, stroke, and death due to vascular causes. The goals of treatment are to prevent future major coronary and cerebrovascular events and improve leg symptoms.
Objective To review the best evidence for medical treatment of PAD.
Evidence Acquisition MEDLINE and the Cochrane database were searched from 1990 to November 2005 for randomized trials and meta-analyses of medical treatments for PAD. References from these articles were also searched. Search terms included, singly and in combination: peripheral arterial disease, peripheral artery disease, PAD, randomized controlled trial, controlled trial, randomized, and meta-analysis. Particular attention was directed toward randomized controlled trials and meta-analyses of clinically relevant medical treatments for PAD. Outcome measures included leg symptoms (intermittent claudication and walking distance), death, and major coronary and cerebrovascular events.
Evidence Synthesis Symptoms of leg claudication, walking distance, and quality of life can be improved by smoking cessation (physician advice, nicotine replacement therapy, and bupropion), a structured exercise program, statin drugs, cilostazol, and angiotensin-converting enzyme inhibitors. The risk of major coronary and cerebrovascular events can be reduced through lowering blood pressure with angiotensin-converting enzyme inhibitors and other antihypertensive drugs, use of statin drugs, antiplatelet therapy with aspirin or clopidogrel, and probably by stopping smoking.
Conclusion The substantial and increasing burden of PAD, and its local and systemic complications, can be reduced by lifestyle modification (smoking cessation, exercise) and medical therapies (nicotine replacement therapy, bupropion, antihypertensive drugs, statins, and antiplatelet drugs).
Author Affiliations: Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth (Dr Hankey); School of Surgery and Pathology, University of Western Australia (Dr Norman); and Department of Medicine, McMaster University, Hamilton, Ontario (Dr Eikelboom).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Policosanol (10 mg/d) Versus Aspirin (100 mg/d) in Patients With Intermittent Claudication: A 10-Week, Randomized, Comparative Study
Illnait et al.
ANGIOLOGY 2008;59:269-277.
ABSTRACT
Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Sobel and Verhaeghe
Chest 2008;133:815S-843S.
ABSTRACT
| FULL TEXT
Therapeutic Angiogenesis Using Tissue Engineered Human Smooth Muscle Cell Sheets
Hobo et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:637-643.
ABSTRACT
| FULL TEXT
Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease
Badger et al.
ANGIOLOGY 2008;59:57-63.
ABSTRACT
Buflomedil in Peripheral Arterial Disease: Trials and Tribulations
Conte
Circulation 2008;117:717-719.
FULL TEXT
Oral Buflomedil in the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Obstructive Disease: A Randomized, Placebo-Controlled, 4-Year Study
Limbs International Medicinal Buflomedil (LIMB) St
Circulation 2008;117:816-822.
ABSTRACT
| FULL TEXT
Ankle-to-Brachial Index and Dementia: The Honolulu-Asia Aging Study
Laurin et al.
Circulation 2007;116:2269-2274.
ABSTRACT
| FULL TEXT
{beta}2-Microglobulin as a Biomarker in Peripheral Arterial Disease: Proteomic Profiling and Clinical Studies
Wilson et al.
Circulation 2007;116:1396-1403.
ABSTRACT
| FULL TEXT
Current Treatment of Peripheral Arterial Disease: Role of Percutaneous Interventional Therapies
Mahmud et al.
J Am Coll Cardiol 2007;50:473-490.
ABSTRACT
| FULL TEXT
Intermittent Claudication
White
NEJM 2007;356:1241-1250.
FULL TEXT
Increasing Survival of Ischemic Tissue by Targeting CD47
Isenberg et al.
Circ. Res. 2007;100:712-720.
ABSTRACT
| FULL TEXT
Medical management of peripheral arterial disease.
Hackam
JAMA 2006;296:41-41.
FULL TEXT
Medical management of peripheral arterial disease.
Finucane
JAMA 2006;296:41-41.
FULL TEXT
|
